Darolutamide: Will it redefine the initial treatment strategy in metastatic prostate cancer?

By Lila Rouland | Published on November 12, 2025 | 3 min read


For many years, metastatic castration-sensitive prostate cancer (mCSPC) was treated exclusively with androgen deprivation therapy (ADT). However, recent therapeutic advances have led to the emergence of combination strategies, particularly those involving androgen receptor signaling inhibitors (ARSi). Among these agents, darolutamide, already validated in non-metastatic castration-resistant prostate cancer, has gained increasing attention for earlier use in treatment. The ARANOTE study, recently published, assessed the efficacy of darolutamide combined with ADT compared with ADT alone in patients with mCSPC who had not received prior chemotherapy, addressing a clinical gap left by major trials such as ARASENS.